In a report by researchers at Will Cornell and the New York Genomics Center, gene mutations that frequently occur in cancer cells provide clues to the origin of the diseases and provide a new therapeutic target. More research involving in recombinant human proteins should be conducted.

Scientists used a new generation of speed technology to trace back to the root of the destruction of protein sequence mutations. As a result, cells create extremely active protein types or dysfunctional protein types that ultimately lead to cancer. "What we need to know next is whether they affect the development of cancer," the scientist said.

In this study, the scientists analyzed cancer samples in the database, focused on 98% of the genome that did not encode the protein, and they initially focused on lung adenocarcinoma, the most common type of lung cancer. They found that the most common mutations in the genome were at the surface activity of gene-encoding protein. Although these genes are essential for healthy lung function, they are not associated with lung cancer. However, in the cell types of lung adenocarcinoma, they are highly expressed.

The researchers then looked at the other 12 genomes of the cancer and found that such genomes were also present in liver, stomach and thyroid tumors. "They are the most famous carcinogenic mutations, and the frequency of mutations in any genes and sequences plays a crucial role in the development of cancer, and it is a welcome finding that these mutations can help us diagnose the lives of cancer," the researchers said. "Markers can be used when the cancer cells are transferred or can't find the original tumor." By the way, Flarebio offers high-quality recombinant proteins like recombinant TLR2 at competitive prices.